Validation of a new instrument for assessing attitudes on psychedelics in the general population.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2022
29 10 2022
Historique:
received:
29
07
2022
accepted:
25
10
2022
entrez:
30
10
2022
pubmed:
31
10
2022
medline:
2
11
2022
Statut:
epublish
Résumé
Although there is research interest to assess attitudes on psychedelics, no validated instrument exists for this purpose. We aimed to develop and examine the psychometric properties of the Attitudes on Psychedelics Questionnaire (APQ) in a sample of the Croatian general population. A cross-sectional, web-based survey among the general population was conducted on 1153 participants (62.1% female, 77.7% with a graduate or high school degree, 15.1% health care workers). We assessed participants' ability to recognize psychedelic substances using a short knowledge test. The APQ consists of 20 items with four sub-scales: Legal Use of Psychedelics, Effects of Psychedelics, Risk Assessment of Psychedelics, and Openness to Psychedelics. This model demonstrated best fit in a confirmatory factor analysis. Total scale reliability was excellent (McDonald's ω = 0.949, 95% CI = 0.944-0.953). A strong correlation with a similar unvalidated measure (r = 0.885, P < 0.001) demonstrated convergent validity. We observed an association between attitudes and knowledge on psychedelics (r = 0.494, P < 0.001). Younger age, male gender, and lower educational status were associated with higher APQ scores. The APQ is valid, reliable, and could be applied in assessing educational interventions, patients' treatment outcomes, and the attitudes of different groups of experts. We encourage further validation of the APQ in English.
Identifiants
pubmed: 36309539
doi: 10.1038/s41598-022-23056-5
pii: 10.1038/s41598-022-23056-5
pmc: PMC9617880
doi:
Substances chimiques
Hallucinogens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18225Subventions
Organisme : Hrvatska Zaklada za Znanost
ID : IP-2019-04-4882
Informations de copyright
© 2022. The Author(s).
Références
Neuropharmacology. 2018 Nov;142:143-166
pubmed: 29753748
J Psychoactive Drugs. 2014 Jan-Mar;46(1):3-10
pubmed: 24830180
J Clin Epidemiol. 2021 Jan;129:151-157
pubmed: 32979491
Pharmaceuticals (Basel). 2021 Aug 12;14(8):
pubmed: 34451890
Nat Med. 2021 Oct;27(10):1687-1688
pubmed: 34635858
Front Psychol. 2020 Jul 10;11:1681
pubmed: 32754101
Psychol Med. 2020 Dec;50(16):2655-2666
pubmed: 33143790
Pharmacol Ther. 2019 May;197:83-102
pubmed: 30521880
Psychol Methods. 2016 Sep;21(3):369-87
pubmed: 27571021
Nature. 2021 Jan;589(7842):474-479
pubmed: 33299186
J Nerv Ment Dis. 2018 Jun;206(6):476-480
pubmed: 29781894
Nat Med. 2021 Jun;27(6):1025-1033
pubmed: 33972795
Sci Rep. 2017 Nov 9;7(1):15201
pubmed: 29123145
Sci Rep. 2021 Nov 23;11(1):22166
pubmed: 34815421
Am J Psychiatry. 2020 May 1;177(5):391-410
pubmed: 32098487
Front Psychol. 2016 May 26;7:769
pubmed: 27303333
Int J Environ Res Public Health. 2021 Aug 02;18(15):
pubmed: 34360453
Mol Biol Rep. 2020 Dec;47(12):9791-9799
pubmed: 33231817
Neurosci Biobehav Rev. 2020 Jun;113:179-189
pubmed: 32194129
J Psychiatr Res. 2021 May;137:273-282
pubmed: 33730602
J Am Coll Health. 2021 Nov-Dec;69(8):889-896
pubmed: 31995455
Expert Rev Clin Pharmacol. 2018 Sep;11(9):889-902
pubmed: 30102078
Front Pharmacol. 2018 Jul 05;9:733
pubmed: 30026698
J Neurol Sci. 2020 Apr 15;411:116715
pubmed: 32044687
Ir J Med Sci. 2022 Jun;191(3):1385-1397
pubmed: 34131812
J Psychoactive Drugs. 1998 Oct-Dec;30(4):333-41
pubmed: 9924839
J Psychoactive Drugs. 2018 Nov-Dec;50(5):460
pubmed: 30376643
Expert Rev Clin Pharmacol. 2021 Sep;14(9):1133-1152
pubmed: 34038314
JAMA Psychiatry. 2021 May 1;78(5):469-470
pubmed: 33263720
Prev Med. 2021 Nov;152(Pt 1):106524
pubmed: 34538369
Int Rev Psychiatry. 2018 Aug;30(4):291-316
pubmed: 30422079
Lancet Psychiatry. 2020 Oct;7(10):829-830
pubmed: 32949507
J Pers Soc Psychol. 1999 Dec;77(6):1121-34
pubmed: 10626367
Addiction. 2021 May;116(5):1152-1161
pubmed: 32949418
Front Pharmacol. 2018 Nov 02;9:897
pubmed: 30450045
Neuropsychopharmacology. 2017 Oct;42(11):2105-2113
pubmed: 28443617
J Psychoactive Drugs. 2022 Sep-Oct;54(4):309-318
pubmed: 34468293
Psychopharmacology (Berl). 2022 Jan;239(1):15-33
pubmed: 34812901
Prev Med. 2017 Nov;104:13-23
pubmed: 28705601
Expert Rev Neurother. 2020 Dec;20(12):1263-1273
pubmed: 32954860
Int J Mol Sci. 2021 Aug 28;22(17):
pubmed: 34502248
Psychol Med. 2021 Oct 21;:1-6
pubmed: 34670633